Unlearn.AI, a San Francisco, CA-based startup that has built a machine learning platform that creates "digital twin" profiles of patients in clinical trials, raised $15 million to expand partnerships and accelerate regulatory approval.
The investment from Radical Ventures and Wittington Ventures valued the startup at $265 million.
The funding Unlearn raised came after it won approval from the European Medicines Agency (EMA) in September for using its AI-driven approach for conducting smaller and quicker clinical trials and struck several multi-million dollar deals with pharmaceutical companies, including Merck.
Unlearn focuses on a relatively novel application of generative AI. While generative AI is known for creating content like text, images, and even computer code, Unlearn uses it to build digital twins to speed up clinical drug trials through its neural networks.
If successful, Unlearn's software could lower costs for drug developers by cutting the number of enrollments needed for clinical trials by replacing patients who receive a placebo.
Mira Murati, chief technology officer at Microsoft-backed OpenAI, is joining the startup's board.
Company: Unlearn.AI, Inc.
Raised: $15.0M
Round: Unknown
Funding Month: March 2023
Lead Investors: Radical Ventures and Wittington Ventures
Additional Investors:
Company Website: https://www.unlearn.ai/
Software Category: AI-based Clinical Trial Management Software
About the Company: Unlearn.AI is a biotech AI startup developing 'digital twin' technology for clinical trial applications. It uses AI to simulate potential health outcomes for individual patients. By collecting patient data from research studies, Unlearn's platform computes a twin for each patient in a clinical trial and populates the control arm of the research with these twins. Unlearn’s technology is used by leading global pharmaceutical companies, including Merck KGaA, Darmstadt, Germany, and has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics. Unlearn.AI aims to build the best AI company in healthcare and is hiring ambitious, gritty innovators with the determination to build the future.
Source: https://www.reuters.com/technology/biotech-ai-startup-unlearn-adds-15-mln-openai-cto-board-2023-03-21/
/